Abstract
Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29–83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a fraction of noncompliant PAP therapy patients, the landscape of sleep medicine and sleep technology is changing to narrow the gap between compliant and non-compliant patients. The remedē® System for treating central sleep apnea and the Inspire® upper airway stimulation (UAS) therapy for treating obstructive sleep apnea are providing new tools for sleep physicians, elevating sleep technologists’ expertise, and paving the way for personalized medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 116-125 |
| Number of pages | 10 |
| Journal | Neurodiagnostic Journal |
| Volume | 58 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 3 2018 |
| Externally published | Yes |
Keywords
- Central sleep apnea
- Inspire upper airway stimulation therapy
- implant
- respicardia remedē system
- sleep apnea
Fingerprint
Dive into the research topics of 'Novel Therapies for Sleep Apnea—The Implants Have Arrived!'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver